Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: <i>In Vitro</i> and Molecular Docking Studies.

Eliaa, Shenouda G; Al-Karmalawy, Ahmed A; Saleh, Rasha M; Elshal, Mohamed F

Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: In Vitro and Molecular Docking Studies.

Eliaa, Shenouda G; Al-Karmalawy, Ahmed A; Saleh, Rasha M; Elshal, Mohamed F.

Afiliação

Eliaa SG; Department of Molecular Biology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City 32897, Egypt.
Al-Karmalawy AA; Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt.
Saleh RM; Department of Physiology, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt.
Elshal MF; Department of Molecular Biology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City 32897, Egypt.

ACS Pharmacol Transl Sci ; 3(6): 1330-1338, 2020 Dec 11.

Article em En | MEDLINE | ID: mdl-33344906

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Pharmacol Transl Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Egito

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google